Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thrombosis 2Venous Thromboembolism 2Pulmonary Embolism 2Thrombosis 1Thromboembolism 1Thrombocytopenia 1Neoplasms 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × apixaban × 90 days × Clear all
NCT06886516 2026-04-15

Apixaban in Thrombocytopenia

Beth Israel Deaconess Medical Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Classical hematology

Pulmonary Embolism, Thrombocytopenia, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism

NCT07493304 2026-03-25

ROXI-CAT-II

Regeneron Pharmaceuticals

Phase 3 Not yet recruiting
1,600 enrolled
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡